Schering-Plough to develop Centocor arthritis treatment

Johnson & Johnson biotech subsidiary Centocor won backing from Schering-Plough on its developmental treatment for rheumatoid arthritis. In exercising previously acquired rights to jointly develop the drug, a monoclonal antibody, Schering-Plough is taking on $125 million in Centocor's previous R&D costs and will share future costs of getting the drug to market. In exchange, Schering-Plough will get some exclusive marketing rights, similar to its deal with Centocor on Remicade.

- read this AP story for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.